Clinical Trial Update: "PTHrP(1-36) IV Dose Escalation Study" [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intravenous PTHrP(1-36) dose escalation for osteoporosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• PTHrP(1-36) (PTHrP(1-36))

Snippet

Sponsor: University of Pittsburgh | Conditions: Osteoporosis | Phase 1 | Status: WITHDRAWN